ADMA Biologics, Inc.
ADMA
$8.41
$0.536.73%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -0.27% | 18.39% | 12.00% | 13.80% | 40.22% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -0.27% | 18.39% | 12.00% | 13.80% | 40.22% |
| Cost of Revenue | -37.17% | -7.14% | -2.63% | 10.09% | 25.58% |
| Gross Profit | 32.17% | 40.24% | 26.76% | 17.01% | 56.23% |
| SG&A Expenses | 9.62% | 0.18% | 17.71% | 33.14% | 52.40% |
| Depreciation & Amortization | 120.00% | 104.00% | 35.71% | -77.46% | -87.05% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -19.67% | -3.55% | 3.75% | 16.47% | 33.08% |
| Operating Income | 44.19% | 63.74% | 28.69% | 9.18% | 59.85% |
| Income Before Tax | 70.78% | 77.44% | 29.30% | 11.84% | 81.78% |
| Income Tax Expenses | 80.25% | 115.83% | 1,219.88% | 55.13% | 1,000.17% |
| Earnings from Continuing Operations | 68.48% | -55.87% | 1.45% | 6.73% | 51.10% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 68.48% | -55.87% | 1.45% | 6.73% | 51.10% |
| EBIT | 44.19% | 63.74% | 28.69% | 9.18% | 59.85% |
| EBITDA | 41.47% | 60.92% | 27.56% | 8.75% | 53.96% |
| EPS Basic | 69.76% | -56.16% | -0.26% | 2.76% | 45.37% |
| Normalized Basic EPS | 48.01% | 70.32% | 32.99% | 10.79% | 75.10% |
| EPS Diluted | 72.73% | -52.82% | 0.00% | 7.69% | 41.39% |
| Normalized Diluted EPS | 49.88% | 72.76% | 35.29% | 12.11% | 75.72% |
| Average Basic Shares Outstanding | -0.72% | 0.65% | 1.72% | 3.90% | 3.89% |
| Average Diluted Shares Outstanding | -1.93% | -0.83% | -0.06% | 2.66% | 3.49% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |